Is AKBA or ALKS more undervalued in 2026?

CirclFi compares Akebia Therapeutics, Inc. (AKBA) and Alkermes plc (ALKS) using 13 institutional-grade valuation models. AKBA has a Quality of Company score of 6.8/10 while ALKS scores 8.7/10.

Which is a better buy — AKBA or ALKS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AKBA and ALKS valuations compare?

AKBA at $1.05 and ALKS at $39.94 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AKBA vs ALKS Valuation Comparison 2026 — Intrinsic Value Analysis

AKBA

Drug Manufacturers - Specialty & Generic

Akebia Therapeutics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$1.05

Last close

Models

12/13

Active

ALKS

Drug Manufacturers - Specialty & Generic

Alkermes plc

Quality

8.7

out of 10

Value Trap

SAFE

Price

$39.94

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	AKBA Fair Value	AKBA Upside	ALKS Fair Value	ALKS Upside
Bayesian DCF	Intrinsic	$3.75	+257.2%	$13.78	-65.5%
Earnings Power Value	Intrinsic	$1.01	-3.9%	$0.82	-97.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AKBA vs ALKS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AKBA vs ALKS — Which Stock Is More Undervalued?

ALKS scores higher with a 8.7/10 quality rating vs AKBA's 6.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Akebia Therapeutics, Inc. (AKBA) and Alkermes plc (ALKS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AKBA currently trades at $1.05 with a QOC of 6.8/10, while ALKS trades at $39.94 with a QOC of 8.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).